| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CK7 |
| Uniprot No | P08729 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-469aa |
| 氨基酸序列 | MSIHFSSPVFTSRSAAFSGRGAQVRLSSARPGGLGSSSLYGLGASRPRVA VRSAYGGPVGAGIREVTINQSLLAPLRLDADPSLQRVRQEESEQIKTLNN KFASFIDKVRFLEQQNKLLETKWTLLQEQKSAKSSRLPDIFEAQIAGLRG QLEALQVDGGRLEAELRSMQDVVEDFKNKYEDEINRRTAAENEFVVLKKD VDAAYMSKVELEAKVDALNDEINFLRTLNETELTELQSQISDTSVVLSMD NSRSLDLDGIIAEVKAQYEEMAKCSRAEAEAWYQTKFETLQAQAGKHGDD LRNTRNEISEMNRAIQRLQAEIDNIKNQRAKLEAAIAEAEERGELALKDA RAKQEELEAALQRAKQDMARQLREYQELMSVKLALDIEIATYRKLLEGEE SRLAGDGVGAVNISVMNSTGGSSSGGGIGLTLGGTMGSNALSFSSSAGPG LLKAYSIRTASASRRSARD |
| 预测分子量 | 78 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于CK7重组蛋白的示例参考文献(内容为虚构，仅供格式参考)：
---
1. **文献名称**: *Production and Characterization of Recombinant Human Cytokeratin 7 for Diagnostic Applications*
**作者**: Li X, et al.
**摘要**: 研究报道了通过大肠杆菌系统高效表达CK7重组蛋白的优化方法，并验证其在免疫组化中作为腺癌诊断标志物的特异性，为临床抗体开发提供基础。
2. **文献名称**: *Structural Insights into CK7 Recombinant Protein Binding to Epithelial Cancer Biomarkers*
**作者**: Martinez R, et al.
**摘要**: 通过X射线晶体学解析CK7重组蛋白的三维结构，揭示了其与上皮性肿瘤标志物相互作用的分子机制，助力靶向药物设计。
3. **文献名称**: *CK7 Recombinant Protein-Based ELISA for Early Detection of Ovarian Carcinoma*
**作者**: Wang H, et al.
**摘要**: 开发了一种基于CK7重组蛋白的ELISA检测法，可显著提高卵巢癌早期诊断灵敏度，临床样本验证显示其特异性优于传统方法。
---
注：以上文献信息为模拟生成，实际研究需通过PubMed/Google Scholar等平台检索真实文献。
Cytokeratin 7 (CK7), a member of the intermediate filament protein family, is a type II epithelial keratin encoded by the *KRT7* gene. It is primarily expressed in glandular and ductal epithelia, including tissues like the breast, lung, pancreas, and urinary tract. As a structural protein, CK7 contributes to cellular integrity, mechanical stability, and stress resistance. Its tissue-specific expression profile has made it a valuable biomarker in diagnostic pathology, particularly for distinguishing carcinomas of epithelial origin (e.g., lung adenocarcinoma, ovarian serous carcinoma) from other malignancies.
Recombinant CK7 is engineered using genetic cloning techniques, where the *KRT7* gene is inserted into expression systems (e.g., *E. coli*, mammalian cells) to produce purified, high-purity proteins. This recombinant form retains the immunogenic and functional properties of native CK7. enabling applications in antibody production, immunohistochemistry (IHC), and *in vitro* studies. Researchers utilize recombinant CK7 to standardize diagnostic assays, investigate epithelial-mesenchymal transition (EMT) in cancer metastasis, and explore drug responses in CK7-positive tumors.
In clinical settings, CK7 is often paired with CK20 for tumor subtyping; for example, CK7+/CK20− profiles are typical in lung and ovarian cancers, while CK7−/CK20+ patterns suggest colorectal origins. Recombinant CK7 also supports the development of targeted therapies and companion diagnostics. Its production in controlled systems minimizes batch variability, enhancing experimental reproducibility. Overall, recombinant CK7 serves as a critical tool in both basic research and translational medicine, bridging molecular insights with clinical diagnostics and therapeutic innovation.
×
